Investigating the Relationship Between Lipid-Lowering Agents and the Complications of Diabetic Retinopathy.

IF 0.9 4区医学 Q4 OPHTHALMOLOGY

Ophthalmic surgery, lasers & imaging retina Pub Date : 2024-12-01 Epub Date: 2024-08-01 DOI:10.3928/23258160-20240729-03

Hejin Jeong, Jacqueline K Shaia, Katherine E Talcott, Rishi P Singh

{"title":"Investigating the Relationship Between Lipid-Lowering Agents and the Complications of Diabetic Retinopathy.","authors":"Hejin Jeong, Jacqueline K Shaia, Katherine E Talcott, Rishi P Singh","doi":"10.3928/23258160-20240729-03","DOIUrl":null,"url":null,"abstract":"Background and objective: As the therapeutic efficacy of lipid-lowering agents (LLA) against diabetic retinopathy (DR) remains controversial, this study aimed to evaluate whether various LLA therapies are associated with a reduced risk of DR progression.Patients and methods: This retrospective study of the medical records of adults with type 2 diabetes mellitus and DR compared the risk of adverse progression of DR between patients who received statins, fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and no LLA (control).Results: Patients in the statin cohort had a reduced rate of progression to proliferative DR compared to controls (HR = 0.30, CI = 0.11 to 0.83). The PCSK9 inhibitor cohort had a reduced risk of progressing to other secondary complications of DR compared to the control (RR = 0.52, CI = 0.43 to 0.64), statin (RR = 0.69, CI = 0.61 to 0.79), and fibrate (RR = 0.67, CI = 0.59 to 0.77) cohorts.Conclusions: These findings suggest use of statins and PCSK9 inhibitors are associated with a reduced risk of adverse progression of DR. [Ophthalmic Surg Lasers Imaging Retina 2024;55:706-713.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"706-713"},"PeriodicalIF":0.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20240729-03","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: As the therapeutic efficacy of lipid-lowering agents (LLA) against diabetic retinopathy (DR) remains controversial, this study aimed to evaluate whether various LLA therapies are associated with a reduced risk of DR progression.

Patients and methods: This retrospective study of the medical records of adults with type 2 diabetes mellitus and DR compared the risk of adverse progression of DR between patients who received statins, fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and no LLA (control).

Results: Patients in the statin cohort had a reduced rate of progression to proliferative DR compared to controls (HR = 0.30, CI = 0.11 to 0.83). The PCSK9 inhibitor cohort had a reduced risk of progressing to other secondary complications of DR compared to the control (RR = 0.52, CI = 0.43 to 0.64), statin (RR = 0.69, CI = 0.61 to 0.79), and fibrate (RR = 0.67, CI = 0.59 to 0.77) cohorts.

Conclusions: These findings suggest use of statins and PCSK9 inhibitors are associated with a reduced risk of adverse progression of DR. [Ophthalmic Surg Lasers Imaging Retina 2024;55:706-713.].

查看原文本刊更多论文

研究降脂药与糖尿病视网膜病变并发症之间的关系。

背景和目的：由于降脂药物（LLA）对糖尿病视网膜病变（DR）的疗效仍存在争议，本研究旨在评估各种 LLA 疗法是否与降低 DR 进展风险有关：这项回顾性研究收集了患有2型糖尿病和DR的成人患者的病历资料，比较了接受他汀类药物、纤维素类药物、9型丙蛋白转换酶亚基酶/kexin（PCSK9）抑制剂治疗的患者与未接受LLA治疗的患者（对照组）之间DR不良进展的风险：与对照组相比，他汀类药物组患者进展为增殖性DR的比率降低（HR = 0.30，CI = 0.11至0.83）。与对照组（RR = 0.52，CI = 0.43至0.64）、他汀类药物组（RR = 0.69，CI = 0.61至0.79）和纤维酸盐组（RR = 0.67，CI = 0.59至0.77）相比，PCSK9抑制剂组发展为DR其他继发性并发症的风险降低：这些研究结果表明，使用他汀类药物和 PCSK9 抑制剂与降低 DR 的不良进展风险有关。[眼科手术激光成像视网膜2024;55:XX-XX]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.